Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

PURPOSE: BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor, has pronounced activity in patients with metastatic melanoma, but its activity in patients with BRAF V600E–positive me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Kopetz, Scott, Desai, Jayesh, Chan, Emily, Hecht, Joel Randolph, O'Dwyer, Peter J., Maru, Dipen, Morris, Van, Janku, Filip, Dasari, Arvind, Chung, Woonbook, Issa, Jean-Pierre J., Gibbs, Peter, James, Brian, Powis, Garth, Nolop, Keith B., Bhattacharya, Suman, Saltz, Leonard
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669589/
https://ncbi.nlm.nih.gov/pubmed/26460303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.2497
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados